SMMT

SMMT

USD

Summit Therapeutics Inc. Common Stock

$17.490-0.290 (-1.631%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$17.780

高値

$18.120

安値

$17.370

出来高

2.88M

企業ファンダメンタルズ

時価総額

13.0B

業種

バイオテクノロジー

United States

取引統計

平均出来高

4.10M

取引所

NGM

通貨

USD

52週レンジ

安値 $15.55現在値 $17.490高値 $36.91

関連ニュース

BusinessWire

Summit Therapeutics to Present at Upcoming Investor Conferences

Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this year. Members of the

もっと見る
Summit Therapeutics to Present at Upcoming Investor Conferences
BusinessWire

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Conducted by Akeso, HARMONi-A Represents the First Statistically Significant OS Benefit Achieved in a Phase III Study by an Ivonescimab-Containing Regimen Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the

もっと見る
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
Analyst Upgrades

Guggenheim Reiterates Buy on Summit Therapeutics, Maintains $40 Price Target

Guggenheim analyst Brad Canino reiterates Summit Therapeutics with a Buy and maintains $40 price target.

もっと見る
Guggenheim Reiterates Buy on Summit Therapeutics, Maintains $40 Price Target
BusinessWire

Summit Therapeutics Raises $500 Million in Private Placement

Fundraise Led by Leading Biopharma Institutional Investors & Insiders $500 Million in Gross & Net Proceeds Raised at Yesterday's Closing Price of $18.74 Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit,"

もっと見る
Summit Therapeutics Raises $500 Million in Private Placement
Analyst Upgrades

Barclays Maintains Underweight on Summit Therapeutics, Raises Price Target to $16

Barclays analyst Etzer Darout maintains Summit Therapeutics with a Underweight and raises the price target from $13 to $16.

もっと見る
Barclays Maintains Underweight on Summit Therapeutics, Raises Price Target to $16
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Summit Therapeutics, Lowers Price Target to $40

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Summit Therapeutics with a Buy and lowers the price target from $50 to $40.

BusinessWire

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

Conference Call to be Held at 8:00am ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October 20, 2025, before the

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。